CORRECTION



Correction: Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study

Nan Jiang $^{1,2} \cdot \text{Ze Zhang}^2 \cdot \text{Xiaoxv Yin}^2 \cdot \text{Huaiming Qiu}^3 \cdot \text{Weipeng Yan}^4 \cdot \text{Yonghong Hao}^1 \cdot \text{Wenhua Yang}^1 \cdot \text{Hualing Li}^1 \cdot \text{Anhui Xu}^1 \cdot \text{Ketao Mu}^{1}$

© Italian Society of Medical Radiology 2024

Correction to:

La radiologia medica (2024) 129:631–642 https://doi.org/10.1007/s11547-024-01781-3

In the original publication of the article, Table 3 was published with errors. The incorrect table and corrected table are provided below:

Incorrect Table 3:

The original article can be found online at https://doi.org/10.1007/s11547-024-01781-3.

- Anhui Xu ahxu@tjmu.edu.cn

Published online: 13 May 2024

- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jie Fang Avenue 1095, Wuhan 430030, China
- School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
- Department of Radiology, PLA Central Military Command General Hospital, Wuhan 430070, China
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China

Table 3 Tumor response after 3 months of treatment before PSM

Tumor response	Patients, No (%)		P value
	SYS plus TACE (n=37)	SYS alone (n=81)	
CR	0 (0.00)	0 (0.00)	_
PR	15 (55.56)	1 (3.70)	_
SD	9 (33.33)	14 (51.85)	_
PD	3 (11.11)	12 (44.44)	_
ORR	18 (48.65)	5 (6.17)	< 0.001
DCR	33 (89.19)	51 (62.96)	0.004

PSM Propensity score matching; *SYS* Systemic chemotherapy; *TACE* Transarterial chemoembolization; *CR* Complete response; *PR* Partial response; *SD* Stable disease; *PD* Progressive disease; *ORR* Objective response rate; *DCR* Disease control rate

Corrected Table 3:

Table 3 Tumor response after 3 months of treatment before PSM

Tumor response	Patients, No (%)		P value
	SYS plus TACE (n=37)	SYS alone (n=81)	
CR	0 (0.00)	0 (0.00)	_
PR	18 (48.65)	5 (6.17)	_
SD	15 (40.54)	46 (56.79)	_
PD	4 (10.81)	30 (37.04)	_
ORR	18 (48.65)	5 (6.17)	< 0.001
DCR	33 (89.19)	51 (62.96)	0.004

PSM Propensity score matching; SYS Systemic chemotherapy; TACE Transarterial chemoembolization; CR Complete response; PR Partial response; SD Stable disease; PD Progressive disease; ORR Objective response rate; DCR Disease control rate

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

